If you are researching a Gardasil injury claim, the litigation's posture matters: after Merck won the central rulings on federal preemption and expert causation, it moved to settle the remaining cases for a comparatively small sum. Here is where MDL 3036 actually stands — reported as litigation, not medical advice.
Allegations Only · Causation Found Unsupported
This page describes litigation and its outcomes. The injury claims described below are unproven allegations, and Merck has not been found liable in any Gardasil trial. Courts in this litigation found the causation evidence insufficient, and the FDA has not required the warnings plaintiffs sought. Nothing here establishes that the vaccine causes these conditions, and nothing here is a recommendation for or against any vaccine — discuss vaccination with your doctor. This page is informational and is not legal or medical advice.
What Is This About?
Gardasil and Gardasil 9 are HPV (human papillomavirus) vaccines made by Merck and given to millions of people, primarily to reduce the risk of certain cancers. Beginning several years ago, a group of people who received the vaccine filed lawsuits alleging it had injured them.The federal cases were consolidated in multidistrict litigation known as MDL 3036, In re: Gardasil Products Liability Litigation, before Judge Kenneth D. Bell in the U.S. District Court for the Western District of North Carolina. It was centralized there in 2022. These are individual injury cases coordinated for pretrial handling; there is no class action.
Anyone researching this litigation should understand its posture clearly. Merck has won the central legal rulings — the marquee failure-to-warn claims were dismissed on federal-preemption grounds, plaintiffs' causation expert was excluded, and a federal appeals court sided with Merck on a threshold procedural question. In June 2026, Merck moved to settle the remaining cases for a comparatively small sum. This is a litigation in wind-down, not an open claims opportunity.
What the Lawsuits Alleged
Plaintiffs alleged that Gardasil caused a range of injuries — most prominently POTS (postural orthostatic tachycardia syndrome, a disorder of heart rate and blood pressure on standing), primary ovarian insufficiency, and other autoimmune conditions. They alleged Merck failed to warn patients and physicians of these risks and overstated the vaccine's benefits.These were contested allegations. Merck disputed them, the FDA has not required POTS or ovarian-insufficiency warnings on the Gardasil label, and — as detailed below — the court found the causation science insufficient to support a warning. Every causal statement here reflects what plaintiffs alleged, not an established fact.
The Vaccine Court Requirement
HPV vaccine claims follow an unusual path. Because these vaccines are covered by the National Childhood Vaccine Injury Act, a claimant generally cannot sue the manufacturer in ordinary civil court first. They must begin in the federal Vaccine Injury Compensation Program (VICP) — the "Vaccine Court" within the U.S. Court of Federal Claims. Only after that process concludes and the petitioner formally rejects the Vaccine Court's judgment may they file a traditional product-liability suit, which is how these cases reached MDL 3036.That gate has mattered. The Vaccine Act imposes a three-year deadline to file the initial Vaccine Court petition, and in Needham v. Merck (decided September 2025), the U.S. Court of Appeals for the Fourth Circuit affirmed the dismissal of bellwether plaintiffs whose underlying petitions were untimely — meaning they had not properly exhausted the VICP process and could not proceed civilly.
The Rulings That Decided the MDL
The litigation turned on two rulings by Judge Bell in 2025:• Implied preemption (March 2025). Judge Bell granted Merck summary judgment on the failure-to-warn claims for the POTS and ovarian-insufficiency bellwethers, holding those state-law claims were impliedly preempted by federal law. Under the Supreme Court's framework, a brand manufacturer can only add a warning through the FDA's "changes-being-effected" route when there is "newly acquired information." The court found the science plaintiffs offered did not qualify and was too thin to support a warning — a ruling that knocked out the large majority of the MDL's POTS and ovarian-insufficiency failure-to-warn cases.
• Expert exclusion. In a companion ruling, the court excluded plaintiffs' regulatory "causation" expert, finding the witness unqualified to opine on a patient-level causal association and lacking a reliable methodology. That reinforced the preemption result.
Together, these rulings — plus the Fourth Circuit's Needham decision on Vaccine Act timeliness — left plaintiffs with little of their case intact.
The ~$50 Million Settlement
After winning those battles, Merck moved to close out the remaining inventory. In June 2026, Bloomberg Law reported that Merck agreed to settle the bulk of the Gardasil litigation — more than 200 cases — for about $50 million, a figure Merck characterized as not material to the company. The reported deal also resolved a closely watched California state-court case that had been headed toward trial.The practical bottom line: this is a resolution reached from a position of strength for the manufacturer, not a plaintiff-driven global settlement, and it is expected to further reduce the small number of cases that remained. There is no public claim form and nothing to file on this page. Anyone who believes they were seriously injured after vaccination should speak with a physician and, if they wish, a qualified attorney about whether any individual avenue remains — but should not expect an open settlement program on these facts.
Frequently Asked Questions
What did the Gardasil lawsuits allege?
Plaintiffs alleged that Merck's Gardasil and Gardasil 9 HPV vaccines caused injuries such as POTS (postural orthostatic tachycardia syndrome), primary ovarian insufficiency, and other autoimmune conditions, and that Merck failed to warn of these risks and overstated the vaccine's benefits. These were contested allegations. Courts in the litigation found the causation evidence insufficient, and no court has ruled that the vaccine causes these conditions.
Do Gardasil claims have to go through the Vaccine Court first?
Generally yes. HPV vaccines are covered by the National Childhood Vaccine Injury Act, so a claimant usually must first file a petition in the federal Vaccine Injury Compensation Program (the "Vaccine Court" in the U.S. Court of Federal Claims). Only after that process concludes and the petitioner rejects the judgment can they bring a product-liability suit against the manufacturer — which is how these cases reached the MDL. The Vaccine Act's three-year filing deadline has been a decisive gate: in 2025 the Fourth Circuit affirmed the dismissal of bellwether plaintiffs whose underlying Vaccine Court petitions were untimely.
Did Merck win the Gardasil litigation?
Largely, on the key legal rulings. In March 2025, Judge Kenneth Bell granted Merck summary judgment on the failure-to-warn claims for the POTS and ovarian-insufficiency bellwethers, holding those state-law claims were impliedly preempted by federal law because the science did not amount to the "newly acquired information" needed to change the label. A separate ruling excluded plaintiffs' causation expert under the reliability standard. The Fourth Circuit also backed Merck on the Vaccine Act timeliness question.
Is there a Gardasil settlement?
In June 2026, Bloomberg Law reported that Merck agreed to settle the bulk of the Gardasil litigation — more than 200 cases — for about $50 million, an amount Merck characterized as not material, and that the deal also resolved a closely watched California state-court case. This came after Merck had won the central preemption and expert rulings, so it represents a wind-down of the remaining inventory rather than a plaintiff-driven global settlement. There is no public claim form on this page.
Does this mean the HPV vaccine is unsafe?
No. This page reports on litigation, not medical guidance. The injury claims are allegations that courts found unsupported on causation, and the FDA has not required POTS or ovarian-insufficiency warnings on the Gardasil label. Nothing here is a recommendation for or against any vaccine — discuss vaccination with your doctor.
Related Mass Torts & Sources
• Zostavax shingles vaccine lawsuit (MDL 2848) — another Merck vaccine MDL whose core cases were dismissed on scientific-proof grounds.• Fosamax femur fracture lawsuit (MDL 2243) — a Merck pharmaceutical MDL that turned on federal-preemption law.
• Dupixent lymphoma lawsuit (MDL 3180) — a newer failure-to-warn drug MDL where causation is unproven.
Primary sources: Judge Bell's March 2025 summary-judgment ruling in In re Gardasil Products Liability Litigation (W.D.N.C.) and the companion expert-exclusion ruling; the Fourth Circuit's Needham v. Merck decision (Sept. 2025) on Vaccine Act timeliness; Bloomberg Law's June 2026 report on the settlement; and the U.S. Judicial Panel on Multidistrict Litigation (JPML) pending-MDL statistics.
Important Disclosures
This page is for general informational purposes and does not constitute medical or legal advice, and it is not a recommendation for or against any vaccine. You should consult a qualified attorney about your individual situation and your doctor about your health. OpenClassActions.com is not a law firm and is not a claims administrator, and this page does not create an attorney-client relationship.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
